DK162519C - Dihydropyridazinonderivater og fremgangsmaade til fremstilling deraf samt farmaceutisk praeparat indeholdende forbindelserne - Google Patents

Dihydropyridazinonderivater og fremgangsmaade til fremstilling deraf samt farmaceutisk praeparat indeholdende forbindelserne

Info

Publication number
DK162519C
DK162519C DK009185A DK9185A DK162519C DK 162519 C DK162519 C DK 162519C DK 009185 A DK009185 A DK 009185A DK 9185 A DK9185 A DK 9185A DK 162519 C DK162519 C DK 162519C
Authority
DK
Denmark
Prior art keywords
compounds
dihydropyridazino
procedures
derivatives
preparing
Prior art date
Application number
DK009185A
Other languages
English (en)
Other versions
DK9185D0 (da
DK9185A (da
DK162519B (da
Inventor
Robert Antony Slater
Original Assignee
Smith Kline French Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smith Kline French Lab filed Critical Smith Kline French Lab
Publication of DK9185D0 publication Critical patent/DK9185D0/da
Publication of DK9185A publication Critical patent/DK9185A/da
Publication of DK162519B publication Critical patent/DK162519B/da
Application granted granted Critical
Publication of DK162519C publication Critical patent/DK162519C/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D237/00Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/22Nitrogen and oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/28Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to cyano groups, e.g. cyanoguanidines, dicyandiamides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/08Vasodilators for multiple indications
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D237/00Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/04Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having less than three double bonds between ring members or between ring members and non-ring members

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Hydrogenated Pyridines (AREA)
DK009185A 1984-01-13 1985-01-08 Dihydropyridazinonderivater og fremgangsmaade til fremstilling deraf samt farmaceutisk praeparat indeholdende forbindelserne DK162519C (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB8400863 1984-01-13
GB848400863A GB8400863D0 (en) 1984-01-13 1984-01-13 Chemical compounds

Publications (4)

Publication Number Publication Date
DK9185D0 DK9185D0 (da) 1985-01-08
DK9185A DK9185A (da) 1985-07-14
DK162519B DK162519B (da) 1991-11-11
DK162519C true DK162519C (da) 1992-03-30

Family

ID=10554924

Family Applications (1)

Application Number Title Priority Date Filing Date
DK009185A DK162519C (da) 1984-01-13 1985-01-08 Dihydropyridazinonderivater og fremgangsmaade til fremstilling deraf samt farmaceutisk praeparat indeholdende forbindelserne

Country Status (31)

Country Link
US (1) US4654342A (da)
EP (1) EP0150937B1 (da)
JP (3) JPS60158181A (da)
KR (1) KR920006781B1 (da)
CN (1) CN85101722A (da)
AT (1) ATE37179T1 (da)
AU (1) AU572252B2 (da)
CA (2) CA1251209A (da)
CS (1) CS248731B2 (da)
DD (1) DD231350A5 (da)
DE (1) DE3564941D1 (da)
DK (1) DK162519C (da)
ES (3) ES8607949A1 (da)
FI (1) FI850140L (da)
GB (1) GB8400863D0 (da)
GR (1) GR850068B (da)
HU (1) HU193591B (da)
IE (1) IE57969B1 (da)
IL (1) IL74031A (da)
JO (1) JO1351B1 (da)
MY (1) MY100124A (da)
NO (1) NO850129L (da)
NZ (1) NZ210816A (da)
PH (1) PH22136A (da)
PL (1) PL147123B1 (da)
PT (1) PT79819B (da)
RO (1) RO92607A (da)
SU (1) SU1396963A3 (da)
WO (1) WO1985003076A1 (da)
ZA (1) ZA85251B (da)
ZW (1) ZW385A1 (da)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1251448A (en) * 1985-03-27 1989-03-21 William J. Coates Pyridazinone derivatives
US4946842A (en) * 1985-07-05 1990-08-07 Smith Kline & French Laboratories Limited Novel guanidino pyridazinones as cardiac stimulants
GB8603780D0 (en) * 1986-02-15 1986-03-19 Smith Kline French Lab Chemical compounds
GB8722776D0 (en) * 1987-09-28 1987-11-04 Smith Kline French Lab Chemical compounds
NZ229828A (en) * 1988-08-09 1992-03-26 Squibb & Sons Inc Aryl cyanoguanidine derivatives and pharmaceutical compositions
US5011837A (en) * 1988-08-09 1991-04-30 E. R. Squibb & Sons, Inc. Aryl cyanoguanidines: potassium channel activators and method of making same
DE60213958T2 (de) * 2001-02-27 2007-08-30 Migenix Corp., San Diego Aryl-n-cyanoguanidine derivate und deren verwendung
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
DE102004011512B4 (de) * 2004-03-08 2022-01-13 Boehringer Ingelheim Vetmedica Gmbh Pharmazeutische Zubereitung enthaltend Pimobendan
US8980894B2 (en) * 2004-03-25 2015-03-17 Boehringer Ingelheim Vetmedica Gmbh Use of PDE III inhibitors for the treatment of asymptomatic (occult) heart failure
EP1579862A1 (en) * 2004-03-25 2005-09-28 Boehringer Ingelheim Vetmedica Gmbh Use of PDE III inhibitors for the reduction of heart size in mammals suffering from heart failure
EP1956906A4 (en) 2005-11-09 2009-12-30 Combinatorx Inc METHODS, COMPOSITIONS AND KITS FOR THE TREATMENT OF PATHOLOGIES
EP3210605A1 (en) * 2005-11-14 2017-08-30 Boehringer Ingelheim Vetmedica GmbH Use of pde iii inhibitors for the treament of asymptomatic (occult) heart failure
EP1920785A1 (en) 2006-11-07 2008-05-14 Boehringer Ingelheim Vetmedica Gmbh Liquid preparation comprising a complex of pimobendan and cyclodextrin
WO2008151257A2 (en) 2007-06-04 2008-12-11 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
WO2009149279A2 (en) 2008-06-04 2009-12-10 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
WO2010009319A2 (en) 2008-07-16 2010-01-21 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
WO2010060874A1 (en) 2008-11-25 2010-06-03 Boehringer Ingelheim Vetmedica Gmbh Phosphodiesterase type iii (pde iii) inhibitors or ca2+-sensitizing agents for the treatment of hypertrophic cardiomyopathy
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
EP3366698A1 (en) 2011-03-01 2018-08-29 Synergy Pharmaceuticals Inc. Guanylate cyclase c agonists
EP2804603A1 (en) 2012-01-10 2014-11-26 President and Fellows of Harvard College Beta-cell replication promoting compounds and methods of their use
US10398705B2 (en) 2012-03-15 2019-09-03 Boehringer Ingelheim Vetmedica Gmbh Pharmaceutical tablet formulation for the veterinary medical sector, method of production and use thereof
CA2902348C (en) 2013-02-25 2021-11-30 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
EP2968439A2 (en) 2013-03-15 2016-01-20 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
JP2016514671A (ja) 2013-03-15 2016-05-23 シナジー ファーマシューティカルズ インコーポレイテッド グアニル酸シクラーゼのアゴニストおよびその使用
CA2913737A1 (en) 2013-06-05 2014-12-11 Synergy Pharmaceuticals, Inc. Ultra-pure agonists of guanylate cyclase c, method of making and using same
DK3021832T3 (da) 2013-07-19 2021-05-25 Boehringer Ingelheim Vetmedica Gmbh Konserverede etherificerede cyclodextrinderivater indeholdende flydende vandig farmaceutisk sammensætning
CN105979959B (zh) 2013-08-09 2021-11-30 阿德利克斯公司 用于抑制磷酸盐转运的化合物和方法
EA201992230A1 (ru) 2013-12-04 2020-02-28 Бёрингер Ингельхайм Ветмедика Гмбх Улучшенные фармацевтические композиции пимобендана
CN104987310A (zh) * 2015-06-03 2015-10-21 青岛农业大学 左西孟旦的合成工艺
US10537570B2 (en) 2016-04-06 2020-01-21 Boehringer Ingelheim Vetmedica Gmbh Use of pimobendan for the reduction of heart size and/or the delay of onset of clinical symptoms in patients with asymptomatic heart failure due to mitral valve disease
CN110117257B (zh) * 2018-02-05 2022-12-06 安徽省新星药物开发有限责任公司 一种含胍基的p2y12受体拮抗剂、制备方法及其用途
WO2020237096A1 (en) 2019-05-21 2020-11-26 Ardelyx, Inc. Combination for lowering serum phosphate in a patient

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3822260A (en) * 1970-10-09 1974-07-02 American Cyanamid Co 6-(cyanophenyl)-4,5-dihydro-3(2h)-pyridazinones
BE791539A (fr) * 1971-11-19 1973-05-17 Basf Ag Dihydropyridazones, leur preparation et leurs utilisations therapeutiques
EP0030835B1 (en) * 1979-12-05 1983-05-11 Morishita Pharmaceutical Co. Ltd. Derivatives of 2-substituted-6-phenyl-3(2h)pyridazinone, their production and pharmaceutical compositions containing them
EP0059688B1 (de) * 1981-03-04 1985-05-15 Ciba-Geigy Ag Pyridazinone, Verfahren zu ihrer Herstellung, pharmazeutische Präparate enthaltend diese Verbindungen und deren Verwendung
JPS58113180A (ja) * 1981-12-28 1983-07-05 Mitsui Toatsu Chem Inc ピリダジノン誘導体
JPS58140076A (ja) * 1982-02-09 1983-08-19 Mitsubishi Chem Ind Ltd ピリダジノン誘導体又はその塩類
DE3204375C2 (de) * 1982-02-09 1983-12-01 J. Rettenmaier & Söhne GmbH + Co, 7091 Holzmühle Verfahren zur Herabsetzung der Saugfähigkeit von Holz
DE3302021A1 (de) * 1983-01-22 1984-07-26 Basf Ag, 6700 Ludwigshafen 6-aryl-4,5-dihydro-3(2h)-pyridazinone, ihre herstellung und verwendung
US4946842A (en) * 1985-07-05 1990-08-07 Smith Kline & French Laboratories Limited Novel guanidino pyridazinones as cardiac stimulants

Also Published As

Publication number Publication date
CA1260471A (en) 1989-09-26
CN85101722A (zh) 1987-01-31
DK9185D0 (da) 1985-01-08
IL74031A (en) 1988-07-31
EP0150937A3 (en) 1985-08-21
ES549629A0 (es) 1987-03-01
PL147123B1 (en) 1989-04-29
ES8703846A1 (es) 1987-03-01
ES554965A0 (es) 1987-07-01
HUT37128A (en) 1985-11-28
CA1251209A (en) 1989-03-14
PL251516A1 (en) 1985-12-17
DK9185A (da) 1985-07-14
SU1396963A3 (ru) 1988-05-15
EP0150937A2 (en) 1985-08-07
HU193591B (en) 1987-11-30
IE850069L (en) 1985-07-13
GB8400863D0 (en) 1984-02-15
PH22136A (en) 1988-06-01
MY100124A (en) 1989-12-18
JPS63313776A (ja) 1988-12-21
CA1260471C (da) 1989-09-26
ES539446A0 (es) 1986-06-01
ZA85251B (en) 1986-08-27
ES8607949A1 (es) 1986-06-01
GR850068B (da) 1985-05-03
AU572252B2 (en) 1988-05-05
US4654342A (en) 1987-03-31
ES8706645A1 (es) 1987-07-01
ATE37179T1 (de) 1988-09-15
JPS63313775A (ja) 1988-12-21
JPS60158181A (ja) 1985-08-19
DD231350A5 (de) 1985-12-24
JO1351B1 (en) 1986-11-30
PT79819B (en) 1987-01-07
CS248731B2 (en) 1987-02-12
FI850140L (fi) 1985-07-14
NO850129L (no) 1985-07-15
PT79819A (en) 1985-02-01
RO92607A (ro) 1987-11-30
ZW385A1 (en) 1985-08-07
KR920006781B1 (ko) 1992-08-17
DK162519B (da) 1991-11-11
DE3564941D1 (en) 1988-10-20
FI850140A0 (fi) 1985-01-11
EP0150937B1 (en) 1988-09-14
IL74031A0 (en) 1985-04-30
AU3761185A (en) 1985-07-18
KR850005417A (ko) 1985-08-26
IE57969B1 (en) 1993-06-02
NZ210816A (en) 1987-06-30
WO1985003076A1 (en) 1985-07-18

Similar Documents

Publication Publication Date Title
DK162519C (da) Dihydropyridazinonderivater og fremgangsmaade til fremstilling deraf samt farmaceutisk praeparat indeholdende forbindelserne
DK158838C (da) Quinazolinderivater, en fremgangsmaade til fremstilling deraf, farmaceutiske praeparater indeholdende derivater samt anvendelse af derivaterne til fremstilling af medikamenter
GB8401093D0 (en) Cephem compounds
DE3772850D1 (de) Thiadiazinon-derivate.
IL79280A (en) 4-(6-oxo-dihydro or tetrahydropyridazin-3-yl)benzene derivatives,their preparation and pharmaceutical compositions containing them
DK105183D0 (da) Fremgangsmade til fremstilling af 1,4-diaminocyclitolderivater

Legal Events

Date Code Title Description
PBP Patent lapsed